Morbidity and medication in a large population of individuals with Down syndrome compared to the general population.
OBJECTIVE
The aim of this study was to describe the incidence of morbidities and the prevalence of medical prescriptions in a large Down syndrome population.


METHODS
A retrospective cohort study was carried out using the UK Clinical Practice Research Datalink from 1 January 2004 to 31 December 2013. We matched individuals with Down syndrome to randomly selected control participants by practice site, sex, birth year, and recording period.


RESULTS
A total of 6430 individuals with Down syndrome (3009 females, 3421 males) and 19 176 controls (8966 females, 10,210 males) were included in the study. The incidence of cardiovascular disorders, gastrointestinal diseases (incidence rate ratio [IRR] 7.9 at 3 to <6y: yearly prevalence ratio [YPR] for laxatives 4.7), and sleeping disorders (IRR 4.8 in 3 to <6y) was increased in children with Down syndrome versus control participants. New onset of congenital heart malformation, ear diseases, eye disorders, autism, hypothyroidism, diabetes, and obesity were more frequent in childhood and remained elevated in adulthood (overall IRR 35.5, 1.7, 3.1, 4.4, 13.1, 1.3, and 2.6 respectively), whereas the gap widened in adulthood for epilepsy and intellectual disability (IRR 15.2 and 158 respectively, in participants older than 30y). At ≥ 30 years, the incidence of hypotension and dementia was raised (IRR 3.0 and 92.1 respectively; YPR for dementia drugs: 76.3); and that of hypertension, depression and anxiety was lowered (IRR 0.2, 0.5, and 0.4 respectively).


CONCLUSIONS
The profile of newly occurring morbidities in Down syndrome varies across the developmental lifespan.
Roche Products Limited, Welwyn Garden City, UK.
Myriam
M
Alexander
Petri Consulting Ltd, St Albans, UK.
Hans
H
Petri
Genesis Research Limited, Hoboken, NJ, USA.
Yingjie
Y
Ding
Roche Product Development, Basel, UK.
Christoph
C
Wandel
Roche Pharmaceutical Research and Early Development, Basel, Switzerland.
Omar
O
Khwaja
Roche Products Limited, Welwyn Garden City, UK.
Nadia
N
Foskett
D000293:Adolescent; D000328:Adult; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D016022:Case-Control Studies; D015897:Comorbidity; D004066:Digestive System Diseases / Q000453:epidemiology*; D004314:Down Syndrome / Q000453:epidemiology*; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D004700:Endocrine System Diseases / Q000453:epidemiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D001523:Mental Disorders / Q000453:epidemiology*; D008659:Metabolic Diseases / Q000453:epidemiology*; D009422:Nervous System Diseases / Q000453:epidemiology*; D015995:Prevalence; D012042:Registries / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D006113:United Kingdom / Q000453:epidemiology; D055815:Young Adult